Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/840
Title: mpMRI is helping to avoid unnecessary prostate biopsies in the diagnostic work-up of prostate cancer.
Epworth Authors: Frydenberg, Mark
Moon, Daniel
Landau, Adam
O'Sullivan, Richard
Grummet, Jeremy
Other Authors: Pepdjonovic, Lana
Huang, Sean
Dat, A.
Mann, Sarah
Hanegbi, Uri
Snow, Ross
Ryan, Andrew
Keywords: Multiparametric Magnetic Resonance Imaging
mpMRI
Prostate Cancer
Diagnosis
Prostate Imaging Reporting and Data System
PI-RADS
Transperineal Prostate Biopsy
TPB
Department of Radiology, Epworth Healthcare, Melbourne, Victoria, Australia
Department of Surgery, Epworth Healthcare, Melbourne, Victoria, Australia
UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
The Epworth Prostate Centre, Epworth Hospital, Victoria, Australia
Issue Date: Jul-2016
Conference: ANZUP Annual Scientific Meeting, GU Cancer: Expanding our Horizons, 10–12 July 2016.
Conference Location: Hilton Brisbane Queensland.
Abstract: INTRODUCTION: Multiparametric magnetic resonance imaging (mpMRI) of the prostate may have a role in prostate cancer diagnosis in reducing the need for prostate biopsies in selected patients. This change in practice has been occurring in the management of patients in a private group urology practice. MATERIALS & METHODS: A custom made REDCap electronic database was used to capture the results of patients who had a mpMRI between June 2013 and January 2016. Information collected included patient age, prostate-specific antigen, Prostate Imaging Reporting and Data System (PI-RADS) score, transperineal biopsy of the prostate (TPB) results and initial management. RESULTS: Of 473 patients undergoing mpMRI, 35 patients had PIRADS 1 and 224 patients PI-RADS 2. Only 37.1% and 33.9% of patients with PIRADS 1 and 2 had a subsequent biopsy, respectively. This is in contrast with 62.5% of PI-RADS 3, 95.8% of PI-RADS 4, and 87.2% of PIRADS 5 patients who went on to have a TPB. The 16 patients who had PIRADS 4 or 5 disease on mpMRI who did not have a TPB had multiple medical comorbidities. CONCLUSION: mpMRI is being used in current clinical practice to avoid biopsy in the diagnostic work-up of prostate cancer in selected patients. However, some patients with negative MRI will have significant disease and therefore those not undergoing a biopsy will need to be followed up closely.
URI: http://hdl.handle.net/11434/840
DOI: 10.1111/ajco.12558
Type: Conference Poster
Affiliated Organisations: Department of Surgery, Monash University, Melbourne, Victoria, Australia.
Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia.
Department of Urology, Alfred Health, Melbourne, Victoria, Australia.
Type of Clinical Study or Trial: Comparative Study
Appears in Collections:Epworth Prostate Centre
Cancer Services
UroRenal, Vascular
Diagnostic Services

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.